High Growth Tech Stocks In Europe To Watch This May 2026

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index ending the week down amid geopolitical tensions and rising energy costs that could lead to inflationary pressures. Despite these headwinds, robust earnings growth in certain sectors highlights opportunities for investors interested in high-growth tech stocks. In this environment, a good stock is typically characterized by strong financial performance and resilience to external economic pressures, making it essential for investors to focus on companies with innovative technologies and solid market positions.

Top 10 High Growth Tech Companies In Europe

Name Revenue Growth Earnings Growth Growth Rating Hacksaw 25.39% 24.80% ★★★★★★ 2CRSI 25.76% 65.41% ★★★★★★ Pharma Mar 17.60% 31.67% ★★★★★☆ Bonesupport Holding 23.74% 34.48% ★★★★★★ Smartoptics Group 23.15% 46.46% ★★★★★★ CD Projekt 31.37% 27.94% ★★★★★☆ KebNi 26.87% 82.69% ★★★★★★ SyntheticMR 18.81% 47.40% ★★★★★☆ BioArctic 24.60% 44.90% ★★★★★★ Sectra 14.73% 22.74% ★★★★★☆

Click here to see the full list of 66 stocks from our European High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Pharma Mar

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pharma Mar, S.A. is a biopharmaceutical company specializing in the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of approximately €1.74 billion.

Operations: The company generates revenue primarily from its oncology segment, amounting to €221.93 million. Operating across multiple international markets, it focuses on the commercialization of bio-active principles for cancer treatment.

Pharma Mar's recent performance and strategic advancements underscore its growing influence in the biotech sector. With a remarkable 304.9% surge in earnings over the past year, significantly outpacing the industry average of 50.1%, and an impressive annual earnings growth forecast at 31.7%, Pharma Mar is setting a robust pace compared to its peers. The company's commitment to innovation is evident from its R&D focus, where recent collaborations aim to revolutionize cancer drug discovery using AI, enhancing both speed and accuracy of research outputs. This approach not only positions Pharma Mar well within a competitive landscape but also aligns with broader industry trends towards integrating advanced technologies for drug development.

Get an in-depth perspective on Pharma Mar's performance by reading our health report here. Evaluate Pharma Mar's historical performance by accessing our past performance report.

Story Continues

BME:PHM Revenue and Expenses Breakdown as at May 2026

Smartoptics Group

Simply Wall St Growth Rating: ★★★★★★

Overview: Smartoptics Group ASA offers optical networking solutions and devices across various regions including the Americas, Europe, the Middle East, Africa, and the Asia-Pacific, with a market cap of NOK5.29 billion.

Operations: Smartoptics Group ASA specializes in providing optical networking solutions and devices globally, focusing on regions such as the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The company operates with a market capitalization of approximately NOK 5.29 billion.

Smartoptics Group ASA has shown a robust trajectory with a 62.6% earnings growth over the past year, significantly outpacing the Communications industry average of 18.2%. This performance is underpinned by substantial revenue growth of 23.2% per year, forecasted to continue surpassing the Norwegian market's expected growth rate of 2% per year. The company's strategic focus on R&D has fostered innovations like their recent deployment with Pilot Fiber in New York, enhancing connectivity solutions up to 400G and supporting high-demand sectors such as trading and AI inference. With an anticipated earnings increase of 46.5% annually, Smartoptics is not only expanding its influence in tech but also setting a strong foundation for sustained future growth.

Take a closer look at Smartoptics Group's potential here in our health report. Gain insights into Smartoptics Group's historical performance by reviewing our past performance report.OB:SMOP Revenue and Expenses Breakdown as at May 2026

BioArctic

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK28.21 billion.

Operations: The company focuses on developing biological drugs for central nervous system disorders. With a market cap of approximately SEK28.21 billion, it operates primarily in Sweden.

BioArctic stands out in the high-growth tech landscape with a projected annual earnings increase of 44.9%, significantly outpacing the Swedish market's average of 8.5%. This robust growth is supported by a revenue uptick expected at 24.6% per year, dwarfing the near-stagnant market projection of 0.02%. Despite a challenging year with earnings down by 76.4%, their commitment to R&D and innovative Alzheimer’s treatments, like Lecanemab, developed in collaboration with Eisai, showcases their potential resilience and contribution to medical technology. Recent trials indicate high treatment persistence rates, underscoring the clinical relevance and potential long-term success of their products in addressing critical health issues.

Click to explore a detailed breakdown of our findings in BioArctic's health report. Review our historical performance report to gain insights into BioArctic's's past performance.OM:BIOA B Revenue and Expenses Breakdown as at May 2026

Turning Ideas Into Actions

Dive into all 66 of the European High Growth Tech and AI Stocks we have identified here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Interested In Other Possibilities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:PHM OB:SMOP and OM:BIOA B.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments